Abstract
Purpose Radiation pneumonitis (RP) is a major dose-limiting toxicity resulting from non-small-cell lung cancer (NSCLC) radiotherapy. Multiomic features (radiomics and dosiomics) could provide additional predictive information as compared to traditionally used clinical and dose-volume histogram (DVH) parameters. We aimed to investigate the utility of multiomic features to improve RP toxicity models.
Methods Out of 329 NSCLC patients considered, 85 patients (25.84%) were found to have toxicity ≥ grade 2 RP per CTCAE v5.0. A total of 422 radiomic and dosiomic features were extracted. Four toxicity prediction model types were created using clinical factors together with respective features from one of the following groups: (a) DVH (base model), (b) whole lung radiomics and dosiomics (WL-RD), (c) multi-region radiomics and dosiomics (MR - RD) and (d) multi-region DVH, radiomics and dosiomics (MR-DVHRD). Toxicity models were created using a random forest classifier with a Monte Carlo cross-validation approach of 100 iterations, and a training/test split of 80%/20%, respectively. Model predictive performance was evaluated by area under the receiver operating characteristic curve (AUC) and area under the precision-recall curve (AUPRC).
Results The AUC and AUPRC values (mean ± standard deviation) for the 4 model types were 0.81±0.04/0.70±0.06 (base model), 0.82±0.05/0.73±0.08 (WL-RD, p<0.05), 0.83±0.06/0.75±0.08 (MR–RD, p<0.05), and 0.82±0.05/0.72±0.08 (MR-DVHRD, p<0.05), respectively, wherein a paired test compared the performance metrics of omic models with the base model built on each iteration of cross0020validation.
Conclusions All multiomic model types outperformed the base DVH model. MR-RD model had the best performance among all model types.
Competing Interest Statement
SSN, RMS, AOL report support through a grant from Varian Medical Systems. XL reports RO1 support for this manuscript and consulting fees from AIQ Global. Inc. LEC reports support from Varian Medical Systems for this manuscript, grants from NCI, CPRIT, Varian Medical Systems, Wellcome and stock from Leo Cancer Care. JSN reports grants from Varian Medical Systems and the Fund for Innovations in Cancer Informatics.
Funding Statement
This study was funded by NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of The University of Texas MD Anderson Cancer Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Research data are stored in an institutional repository and anonymized data will be shared, following a 12 month embargo after the date of publication, upon request to the corresponding author once a data transfer agreement has been reached between the requestors institution and MD Anderson Cancer Center.
